AXIM AXIM BIOTECHNOLOGIES, INC. OTC · United States

AXIM BIOTECHNOLOGIES, INC. (AXIM) news

AXIM BIOTECHNOLOGIES, INC. is a public biotech or pharmaceutical company listed on OTC under the ticker AXIM, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest AXIM BIOTECHNOLOGIES, INC. news

We have not published a story on AXIM BIOTECHNOLOGIES, INC. yet. When there is news, it will appear here.

AXIM BIOTECHNOLOGIES, INC. annual financials

Line	FY2023	FY2022
Revenue	$39,518	$8,875
Research and development	$125,496	$153,697
Net income (loss)	-$8.1 million	-$6.2 million
Cash from operations	-$1.0 million	-$2.0 million
Cash and equivalents	$156,457	$47,282

Latest balance sheet, Jun 30, 2024 (10-Q): cash and equivalents $6,044.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about AXIM BIOTECHNOLOGIES, INC.

What is the ticker symbol of AXIM BIOTECHNOLOGIES, INC.?

AXIM BIOTECHNOLOGIES, INC. trades under the ticker AXIM on OTC.

Where is AXIM BIOTECHNOLOGIES, INC. listed?

AXIM BIOTECHNOLOGIES, INC. is listed on OTC.

Which country or territory is AXIM BIOTECHNOLOGIES, INC. listed under?

Our directory records AXIM BIOTECHNOLOGIES, INC. under United States.

Does aibio.space cover AXIM BIOTECHNOLOGIES, INC.?

aibio.space lists AXIM BIOTECHNOLOGIES, INC. among 2,820 public biotech companies and publishes its news here as stories appear.

What was AXIM BIOTECHNOLOGIES, INC.'s revenue last year?

$39,518 for the fiscal year ended Dec 31, 2023, as reported to the SEC.

Is AXIM BIOTECHNOLOGIES, INC. profitable?

AXIM BIOTECHNOLOGIES, INC. reported a net loss of $8.1 million for the fiscal year ended Dec 31, 2023, and used $1.0 million of cash in operations, per its annual report to the SEC.

How much does AXIM BIOTECHNOLOGIES, INC. spend on research and development?

$125,496 in the fiscal year ended Dec 31, 2023, per its annual report.

How much cash does AXIM BIOTECHNOLOGIES, INC. have?

$6,044 in cash at Jun 30, 2024, per its 10-Q.

Investor discussion: AXIM BIOTECHNOLOGIES, INC.

Members talk about AXIM BIOTECHNOLOGIES, INC. (AXIM). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:AXIM on TradingView.

Listing details

Company: AXIM BIOTECHNOLOGIES, INC.
Ticker: AXIM
Listing: OTC
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction